Literature DB >> 20368833

Expression of matrix metalloproteinase-9 correlates with poor prognosis in human malignant fibrous histiocytoma.

Jinyoung Yoo1, Ji Han Jung, Seok Jin Kang, Chang Suk Kang.   

Abstract

PURPOSE: 92 kDa matrix metalloproteinase-9 (MMP-9) is believed to play an important role in degrading the matrix and basement membrane, contributing to the invasion and metastasis of malignant solid tumors. However, little is known about its involvement in a malignant fibrous histiocytoma. The aim of this study was to investigate the expression of MMP-9 and to correlate its expression with clinicopathologic parameters in human malignant fibrous histiocytomas.
MATERIALS AND METHODS: Archival tumor tissues from 20 patients with a malignant fibrous histiocytoma were analyzed by immunohistochemistry for the expression of MMP-9. Clinical information was obtained through the computerized retrospective database from the tumor registry.
RESULTS: Seventeen of 20 (85%) tumors showed a positive reaction for MMP-9. MMP-9 activity was inversely correlated with patients' survival time (p=.011). There was no significant correlation between the activated MMP-9 expression and all the other clinicopathologic variables.
CONCLUSION: Our data demonstrate that MMP-9 activation is likely to occur in human malignant fibrous histiocytomas. It is also noteworthy that the expression of MMP-9 may aid in predicting patients' poor prognosis.

Entities:  

Keywords:  MMP-9; Malignant histiocytic disorder

Year:  2004        PMID: 20368833      PMCID: PMC2843884          DOI: 10.4143/crt.2004.36.6.384

Source DB:  PubMed          Journal:  Cancer Res Treat        ISSN: 1598-2998            Impact factor:   4.679


  21 in total

Review 1.  New molecular targets and biological therapies in sarcomas.

Authors:  F A Scappaticci; N Marina
Journal:  Cancer Treat Rev       Date:  2001-12       Impact factor: 12.111

Review 2.  Matrix metalloproteinases as targets for therapy in Kaposi sarcoma.

Authors:  B Fingleton; L M Matrisian
Journal:  Curr Opin Oncol       Date:  2001-09       Impact factor: 3.645

Review 3.  Matrix metalloproteinases and metastasis.

Authors:  D E Kleiner; W G Stetler-Stevenson
Journal:  Cancer Chemother Pharmacol       Date:  1999       Impact factor: 3.333

4.  Production of matrix metalloproteinase-9 in early stage B-CLL: suppression by interferons.

Authors:  B Bauvois; J Dumont; C Mathiot; J-P Kolb
Journal:  Leukemia       Date:  2002-05       Impact factor: 11.528

5.  Prognostic significance of matrix metalloproteinases 2 and 9 in bladder cancer.

Authors:  A S Papathoma; C Petraki; A Grigorakis; H Papakonstantinou; V Karavana; S Stefanakis; F Sotsiou; A Pintzas
Journal:  Anticancer Res       Date:  2000 May-Jun       Impact factor: 2.480

6.  Pharmacological inhibition of gelatinase B induction and tumor cell invasion.

Authors:  J I McMillan; R Weeks; J W West; S Bursten; G C Rice; D H Lovett
Journal:  Int J Cancer       Date:  1996-08-07       Impact factor: 7.396

7.  Immunohistochemical study of membrane type-matrix metalloproteinases (MT-MMPs) and matrix metalloproteinase-2 (MMP-2) in dermatofibroma and malignant fibrous histiocytoma.

Authors:  Yoshihiro Ohnishi; Yoshiyasu Ito; Shingo Tajima; Akira Ishibashi; Katsuhiko Arai
Journal:  J Dermatol Sci       Date:  2002-02       Impact factor: 4.563

8.  Inhibition of matrix metalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma model system.

Authors:  J Hua; R J Muschel
Journal:  Cancer Res       Date:  1996-11-15       Impact factor: 12.701

9.  Expression and localization of 92 kDa type IV collagenase/gelatinase B (MMP-9) in human gliomas.

Authors:  J S Rao; M Yamamoto; S Mohaman; Z L Gokaslan; G N Fuller; W G Stetler-Stevenson; V H Rao; L A Liotta; G L Nicolson; R E Sawaya
Journal:  Clin Exp Metastasis       Date:  1996-01       Impact factor: 5.150

10.  Prognostic factors in 227 patients with malignant fibrous histiocytoma.

Authors:  C M Pezzi; M S Rawlings; J J Esgro; R E Pollock; M M Romsdahl
Journal:  Cancer       Date:  1992-04-15       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.